India's Obesity Drug Market on the Brink of Disruption: Can Pharma Giants and Policy Reforms Drive Transformation?

India's anti-obesity drug market has been experiencing steady expansion, primarily driven by the increasing prevalence of obesity and its associated health risks, including diabetes, cardiovascular diseases, and strokes. According to Makreo Research, the market has demonstrated strong growth over the past five years, with revenue surging by INR 324 crores between 2019 and 2024.

For more details, Request the Sample Report from here
https://www.makreo.com/report/india-anti-obesity-drug-market-size-and-forecast-2030

This upward trajectory is expected to persist, with the India Anti-Obesity Drug Market projected to sustain a double-digit growth rate in the coming years. A key factor fueling this growth is the introduction of semaglutide in India, launched by Novo Nordisk in 2022. Currently, this GLP-1 receptor agonist dominates the market, accounting for approximately 66% of the value share in India's obesity drug industry.

► Global Obesity Epidemic and Economic Implications
The global obesity crisis is intensifying, with projections suggesting that by 2030, nearly half of the world's population could be classified as overweight or obese. This rising prevalence is driven by factors such as unhealthy dietary patterns, declining physical activity, and socio-economic inequalities.

The economic impact is substantial, as nations allocate increasing resources to manage obesity-related health complications, including diabetes and cardiovascular diseases. According to the Organisation for Economic Co-operation and Development (OECD), countries are projected to spend an average of USD PPP 209 per capita annually on healthcare costs related to overweight populations between 2020 and 2050. The financial burden varies significantly across regions, with the United States leading at USD PPP 645, largely due to higher medical expenses and obesity prevalence. On average, 8.4% of OECD health budgets will be dedicated to addressing obesity-related issues, amounting to USD PPP 311 billion annually. Across 52 countries, the total yearly expenditure is expected to reach USD PPP 425 billion, a figure comparable to Austria's GDP in 2018.

As obesity rates continue to climb, the demand for pharmaceutical obesity drugs in India and globally is rising, underscoring the need for effective anti-obesity prescription drugs and policy interventions to mitigate long-term health and economic consequences.

► Obesity Trends and Challenges in India
India is witnessing a surge in obesity rates, reflecting global trends while presenting distinct challenges.

• Urban-Rural Disparity: A significant contrast in obesity prevalence exists between urban and rural populations, with cities experiencing higher rates due to sedentary lifestyles and dietary shifts.
• Demographic Influence: The country's predominantly young population is increasingly affected by obesity, raising concerns about long-term health risks.
• Impact of Urbanization: Rapid urban growth has accelerated lifestyle changes, contributing to the rising demand for weight loss drugs in India and other medical interventions.

The growing prevalence of obesity is directly linked to a rise in non-communicable diseases (NCDs) such as diabetes and cardiovascular disorders, placing additional strain on the healthcare system. The economic burden of these conditions is expected to escalate in the coming years.

According to the National Family Health Survey (NFHS) 2022, one in four Indians is overweight. However, India's unique "thin-fat" phenotype, characterized by higher body fat percentages despite smaller frames, challenges conventional global obesity benchmarks. This highlights the need for region-specific health assessments and targeted treatments, fueling the expansion of the India anti-obesity drug market.

► Challenges in the India Anti-Obesity Drug Market
Despite the expanding obesity treatment market in India, several factors continue to limit the widespread adoption of pharmaceutical interventions:

• Limited Awareness: While the demand for anti-obesity prescription drugs in India is growing, particularly among high-income groups, general awareness remains low, restricting accessibility to a niche segment.
• Regulatory Barriers: The India anti-obesity drug regulations involve complex approval processes, delaying the introduction of promising treatments such as tirzepatide, which is already available in other countries.
• Cultural and Social Stigma: Perceptions surrounding obesity and its medical treatment create resistance to seeking pharmaceutical solutions.
• High Treatment Costs: The affordability of weight loss drugs in India remains a concern, limiting their reach to a broader population.
• Unregulated Markets: The presence of gray market channels leads to the availability of unauthorized or counterfeit medications, raising safety concerns.
• Misconceptions About Treatment: A lack of understanding about the efficacy and safety of pharmaceutical obesity drugs in India contributes to hesitancy in adoption.
• Shortage of Specialized Care: The limited availability of healthcare professionals trained in obesity management further restricts the effective prescription and use of these drugs.

Addressing these challenges is essential for the India obesity drug market growth, ensuring broader accessibility to safe and regulated treatment options.

► Industry Initiatives and Future Outlook in the India Anti-Obesity Drug Market
Indian pharmaceutical companies are strengthening their focus on the obesity treatment market in India, leveraging their established expertise in diabetes care. Sun Pharmaceuticals, the country's largest drugmaker by revenue, is developing Utreglutide (GL0034), an experimental GLP-1 receptor agonist in India, aimed at treating obesity and type 2 diabetes. The drug, designed to mimic gut hormones to regulate appetite and metabolic function, is expected to be launched within the next five years.

Global pharmaceutical giants are also advancing obesity drug innovation in India. Eli Lilly has commenced phase-three clinical trials for orforglipron, an oral nonpeptide GLP-1 receptor agonist in India, providing an alternative to injectable therapies like semaglutide and liraglutide. This drug targets both obesity and type 2 diabetes while addressing associated cardiovascular risks.

To enhance affordability and accessibility, the Indian government is actively promoting the local manufacturing of pharmaceutical obesity drugs in India through Production-Linked Incentive (PLI) for Pharma schemes. With Novo Nordisk's semaglutide patent expiring in 2026, the market is set to witness the emergence of generic obesity drugs in India, significantly lowering treatment costs. This initiative aligns with India's ambition to become a key player in the global supply of cost-effective weight loss drugs in India, driving India obesity drug market growth in the coming years.

► Comprehensive Market Analysis on India Anti-Obesity Drug Market
Makreo Research has published an extensive report titled "India Anti-Obesity Drug Market Size and Forecast (2024-2030) - Growth Opportunities by Drug Type, Administration Route, Classification, Distribution Channels, and Geography," offering a detailed analysis of the country's evolving market landscape. The report examines the impact of economic, political, technological, and demographic factors on market dynamics, while assessing historical and current market performance. It also evaluates global obesity trends, comparing them with those in India to analyze their influence on market growth. The study provides a thorough competitive analysis, including profiles of leading market players, and explores the availability, approval status, and anticipated launches of various drugs in India. Furthermore, the report identifies significant challenges facing the market and uncovers growth opportunities that are expected to drive its expansion.

Period of Study:
• 2019 - 2023: Past and Present Scenario
• 2023: Base year of study
• 2024 - 2030: Future Prospects

Competitive Landscape:
This section provides a detailed market comparison of key players in the India anti-obesity drug market based on various parameters. It also highlights their recent investments, mergers and acquisitions (M&A), and funding activities in the market. Additionally, it includes comprehensive profiles of selected industry players, covering their financials and latest business activities.

Companies Covered:
Aristo Pharmaceuticals Pvt. Ltd., Mankind Pharmaceuticals, Torrent Pharmaceuticals Limited, Biocon Pharmaceuticals, SunPharma Pharmaceuticals Industries Ltd., Dr.Reddy's Laboratories Ltd., Cipla Limited, Divi's Laboratories, Novo Nordisk, Eli Lilly and Company, Eris Lifesciences, Leeford Healthcare and Lupin Limited.

Market Segmentation:
• By Drug Type
• By Administration Route
• By Drug Classification
• By Distribution Channels
• By Regions

Key Questions Answered:
• How has India's anti-obesity drug market evolved, and what is its current state?
• What economic, political, technological, and demographic factors influence the market?
• How does global obesity prevalence compare to India's, and what are the key differences?
• What is the approval status of anti-obesity drugs in India?
• How does drug availability vary across different parameters?
• Which anti-obesity drugs were recently launched, and what new ones are expected?
• Who are the major players in the Indian market, and what are their market shares?
• How do leading companies compare in terms of revenue, market share, and pricing?
• What are the key challenges and growth drivers in the market?
• What is the future outlook, and what opportunities exist for growth?

Similar Reports:
India Adult Vaccine Market Report - Global Vaccination Coverage, Demand, Opportunities, Pipeline Vaccines, and Competitive Analysis
https://www.makreo.com/report/india-adult-vaccine-market-report-global-vaccination-coverage-demand-opportunities-pipeline-vaccines-and-competitive-analysis

India Advanced Wound Care Market Size and Forecast (2018-2028) - Growth Opportunities in the Hydrogel Market
https://www.makreo.com/report/india-advanced-wound-care-market-size-forecast-2018-2028-opportunities-hydrogel-market

Looking for a Trusted Partner for Your Retail Market Survey?
Makreo Research has extensive experience conducting retail market surveys across Tier 1 and Tier 2 cities in India, including Mumbai, Delhi, Bangalore, Chennai, Hyderabad, and Indore. Our expertise spans industries like pharmaceuticals, advanced wound care, biodegradable tableware, logistics, and warehousing, assisting both established players and emerging brands in expanding their market presence.

In today's competitive retail landscape, understanding consumer behavior is key to success. Makreo Research offers comprehensive retail market surveys, including Customer Experience, Satisfaction, Pricing, Promotion, Employee Satisfaction, and Mystery Shopping surveys, making us your trusted partner for actionable insights.

Our Retail Market Survey Solutions Include:
• Mystery Shopping: Assess in-store service quality.
• Customer Surveys: Understand preferences and pain points.
• Customer Segmentation: Target key demographics for better marketing.
• Shop-Alongs: Observe real-time shopping behavior.
• Competitive Research: Analyze competitor strategies and pricing.
• Social Listening & Monitoring: Track brand reputation and sentiment online.

Let Makreo Research empower your business with data-driven insights for sustainable retail growth. Contact us today to learn more!
https://www.makreo.com/market-survey

Makreo Research and Consulting
801, Trishul Goldmine, Palm Beach, Sector 15, Belapur, Navi Mumbai, Maharashtra 400614

Contact us:
Phone Number
+91-9619699069
Email Address
info@makreo.com

Makreo Research provides high-quality market insights, helping businesses, governments, and agencies make informed decisions. Based in India, we specialize in Syndicated and Custom Research, Consulting, and Market Surveys, offering deep analysis to navigate complex market dynamics and drive growth.

Extensive Industry Coverage Across Geographies
Makreo Research offers in-depth insights across industries like Logistics, Packaging, Healthcare, BFSI, E-commerce, and more. With a global presence spanning North America, LATAM, Europe, APAC, MENA, and beyond, we cater to both developed and emerging markets, delivering tailored research solutions.

This release was published on openPR.